In search of new therapeutic targets and strategies for heart failure: recent advances in basic science

Choi, 2011, Cardiac cell therapies: the next generation, Cardiovasc Ther, 29, 2, 10.1111/j.1755-5922.2010.00191.x Mudd, 2008, Tackling heart failure in the twenty-first century, Nature, 451, 919, 10.1038/nature06798 Dor, 2007, The fuzzy logic of physiological cardiac hypertrophy, Hypertension, 49, 962, 10.1161/HYPERTENSIONAHA.106.079426 Catalucci, 2008, Physiological myocardial hypertrophy: how and why?, Front Biosci, 13, 312, 10.2741/2681 Frey, 2003, Cardiac hypertrophy: the good, the bad, and the ugly, Annu Rev Physiol, 65, 45, 10.1146/annurev.physiol.65.092101.142243 Dorn, 2005, Protein kinase cascades in the regulation of cardiac hypertrophy, J Clin Invest, 115, 527, 10.1172/JCI24178 Heineke, 2006, Regulation of cardiac hypertrophy by intracellular signalling pathways, Nat Rev Mol Cell Biol, 7, 589, 10.1038/nrm1983 Gautel, 2008, The sarcomere and the nucleus: functional links to hypertrophy, atrophy and sarcopenia, Adv Exp Med Biol, 642, 176, 10.1007/978-0-387-84847-1_13 Santos, 2011, Redox signaling in cardiac myocytes, Free Radic Biol Med, 50, 777, 10.1016/j.freeradbiomed.2011.01.003 Bostrom, 2010, C/EBPβ controls exercise-induced cardiac growth and protects against pathological cardiac remodeling, Cell, 143, 1072, 10.1016/j.cell.2010.11.036 Backs, 2006, Control of cardiac growth by histone acetylation/deacetylation, Circ Res, 98, 15, 10.1161/01.RES.0000197782.21444.8f Trivedi, 2007, Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity, Nat Med, 13, 324, 10.1038/nm1552 Takimoto, 2005, Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy, Nat Med, 11, 214, 10.1038/nm1175 Pokreisz, 2009, Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice, Circulation, 119, 408, 10.1161/CIRCULATIONAHA.108.822072 Latronico, 2011, microRNAs in hypertrophy and heart failure, Exp Biol Med (Maywood), 236, 125, 10.1258/ebm.2010.010269 Topkara, 2010, Clinical applications of miRNAs in cardiac remodeling and heart failure, Per Med, 7, 531, 10.2217/pme.10.44 van Rooij, 2007, Control of stress-dependent cardiac growth and gene expression by a microRNA, Science, 316, 575, 10.1126/science.1139089 Thum, 2008, MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts, Nature, 456, 980, 10.1038/nature07511 da Costa Martins, 2010, MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling, Nat Cell Biol, 12, 1220, 10.1038/ncb2126 van Rooij, 2008, Toward microRNA-based therapeutics for heart disease: the sense in antisense, Circ Res, 103, 919, 10.1161/CIRCRESAHA.108.183426 Tijsen, 2010, MiR423-5p as a circulating biomarker for heart failure, Circ Res, 106, 1035, 10.1161/CIRCRESAHA.110.218297 Zampetaki, 2010, Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes, Circ Res, 107, 810, 10.1161/CIRCRESAHA.110.226357 Lehnart, 2009, Abnormalities of calcium metabolism and myocardial contractility depression in the failing heart, Heart Fail Rev, 14, 213, 10.1007/s10741-009-9146-x Nicolaou, 2009, Role of PP1 in the regulation of Ca cycling in cardiac physiology and pathophysiology, Front Biosci, 14, 3571, 10.2741/3472 Wittkopper, 2010, Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging, J Clin Invest, 120, 617 Shan, 2010, Role of chronic ryanodine receptor phosphorylation in heart failure and beta-adrenergic receptor blockade in mice, J Clin Invest, 120, 4375, 10.1172/JCI37649 George, 2008, Sarcoplasmic reticulum Ca2+ leak in heart failure: mere observation or functional relevance?, Cardiovasc Res, 77, 302, 10.1093/cvr/cvm006 Kohlhaas, 2010, Elevated cytosolic Na+ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes, Circulation, 121, 1606, 10.1161/CIRCULATIONAHA.109.914911 Huang, 2011, G protein-coupled receptor kinases in normal and failing myocardium, Front Biosci, 17, 3057, 10.2741/3898 Ho, 2010, Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5, Heart Fail Rev, 15, 495, 10.1007/s10741-010-9183-5 Frey, 2004, Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress, Nat Med, 10, 1336, 10.1038/nm1132 Wu, 2006, Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling, J Clin Invest, 116, 675, 10.1172/JCI27374 Heineke, 2010, CIB1 is a regulator of pathological cardiac hypertrophy, Nat Med, 16, 872, 10.1038/nm.2181 Lompre, 2010, Ca2+ cycling and new therapeutic approaches for heart failure, Circulation, 121, 822, 10.1161/CIRCULATIONAHA.109.890954 Jaski, 2009, Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial, J Card Fail, 15, 171, 10.1016/j.cardfail.2009.01.013 Malik, 2011, Cardiac myosin activation: a potential therapeutic approach for systolic heart failure, Science, 331, 1439, 10.1126/science.1200113 Whelan, 2010, Cell death in the pathogenesis of heart disease: mechanisms and significance, Annu Rev Physiol, 72, 19, 10.1146/annurev.physiol.010908.163111 Dor, 2009, Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling, Cardiovasc Res, 81, 465 Erickson, 2008, A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation, Cell, 133, 462, 10.1016/j.cell.2008.02.048 Muraski, 2007, Pim-1 regulates cardiomyocyte survival downstream of Akt, Nat Med, 13, 1467, 10.1038/nm1671 Kung, 2011, Programmed necrosis, not apoptosis, in the heart, Circ Res, 108, 1017, 10.1161/CIRCRESAHA.110.225730 Nakagawa, 2005, Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death, Nature, 434, 652, 10.1038/nature03317 Baines, 2005, Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death, Nature, 434, 658, 10.1038/nature03434 Nakayama, 2007, Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure, J Clin Invest, 117, 2431, 10.1172/JCI31060 Diwan, 2009, Endoplasmic reticulum-mitochondria crosstalk in NIX-mediated murine cell death, J Clin Invest, 119, 203 Nishida, 2009, The role of autophagy in the heart, Cell Death Differ, 16, 31, 10.1038/cdd.2008.163 Nakai, 2007, The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress, Nat Med, 13, 619, 10.1038/nm1574 Patterson, 2007, The bitter end: the ubiquitin-proteasome system and cardiac dysfunction, Circulation, 115, 1456, 10.1161/CIRCULATIONAHA.106.649863 Zhu, 2007, Cardiac autophagy is a maladaptive response to hemodynamic stress, J Clin Invest, 117, 1782, 10.1172/JCI27523 Shiojima, 2005, Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure, J Clin Invest, 115, 2108, 10.1172/JCI24682 Sano, 2007, p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload, Nature, 446, 444, 10.1038/nature05602 Heineke, 2007, Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart, J Clin Invest, 117, 3198, 10.1172/JCI32573 Zhang, 2010, NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis, Proc Natl Acad Sci USA, 107, 18121, 10.1073/pnas.1009700107 Ingwall, 2009, Energy metabolism in heart failure and remodelling, Cardiovasc Res, 81, 412, 10.1093/cvr/cvn301 Liu, 2009, Regulation of mitochondrial Ca2+ and its effects on energetics and redox balance in normal and failing heart, J Bioenerg Biomembr, 41, 127, 10.1007/s10863-009-9216-8 Madrazo, 2008, The PPAR trio: regulators of myocardial energy metabolism in health and disease, J Mol Cell Cardiol, 44, 968, 10.1016/j.yjmcc.2008.03.021 Kolwic, 2009, Metabolic therapy at the crossroad: how to optimize myocardial substrate utilization?, Trends Cardiovasc Med, 19, 201, 10.1016/j.tcm.2009.12.005 Hudson, 2006, Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial, J Am Coll Cardiol, 48, 15, 10.1016/j.jacc.2006.02.055 Koitabashi, 2011, Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload, J Clin Invest, 121, 2301, 10.1172/JCI44824 Zeisberg, 2007, Endothelial-to-mesenchymal transition contributes to cardiac fibrosis, Nat Med, 13, 952, 10.1038/nm1613 Takeda, 2010, Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload, J Clin Invest, 120, 254, 10.1172/JCI40295 Del Re, 2010, Proapoptotic Rassf1A/Mst1 signaling in cardiac fibroblasts is protective against pressure overload in mice, J Clin Invest, 120, 3555, 10.1172/JCI43569 Damilano, 2011, Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase gamma activity in pressure overload-induced cardiac failure, Circulation, 123, 391, 10.1161/CIRCULATIONAHA.110.950543 Kawaguchi, 2011, Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury, Circulation, 123, 594, 10.1161/CIRCULATIONAHA.110.982777 Lamkanfi, 2011, Emerging inflammasome effector mechanisms, Nat Rev Immunol, 11, 213, 10.1038/nri2936 Mann, 2005, Targeted anticytokine therapy and the failing heart, Am J Cardiol, 95, 9, 10.1016/j.amjcard.2005.03.007 Mann, 2011, The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls, Circ Res, 108, 1133, 10.1161/CIRCRESAHA.110.226936 Swedberg, 2010, Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study, Lancet, 376, 875, 10.1016/S0140-6736(10)61198-1 Mann, 2005, Mechanisms and models in heart failure: the biomechanical model and beyond, Circulation, 111, 2837, 10.1161/CIRCULATIONAHA.104.500546 Ieda, 2010, Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors, Cell, 142, 375, 10.1016/j.cell.2010.07.002 Carvajal-Vergara, 2010, Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome, Nature, 465, 808, 10.1038/nature09005 Molkentin, 2009, With great power comes great responsibility: using mouse genetics to study cardiac hypertrophy and failure, J Mol Cell Cardiol, 46, 130, 10.1016/j.yjmcc.2008.09.002 Cook, 2009, Are transgenic mice the ‘alkahest’ to understanding myocardial hypertrophy and failure?, J Mol Cell Cardiol, 46, 118, 10.1016/j.yjmcc.2008.11.005 Dixon, 2009, Large animal models of heart failure: a critical link in the translation of basic science to clinical practice, Circ Heart Fail, 2, 262, 10.1161/CIRCHEARTFAILURE.108.814459 Sabbah, 1991, A canine model of chronic heart failure produced by multiple sequential coronary microembolizations, Am J Physiol, 260, H1379 Adams, 2010, Systems biology and heart failure: concepts, methods, and potential implications, Heart Fail Rev, 15, 371, 10.1007/s10741-009-9138-x Efimov, 2010, Multiscale imaging of the human heart: building the foundation for human systems physiology and translational medicine, Conf Proc IEEE Eng Med Biol Soc, 2010, 5177 Sharma, 2005, A systematic review of large scale and heterogeneous gene array data in heart failure, J Mol Cell Cardiol, 38, 425, 10.1016/j.yjmcc.2004.12.016 Drozdov, 2010, Genome-wide expression patterns in physiological cardiac hypertrophy, BMC Genomics, 11, 557, 10.1186/1471-2164-11-557 Dewey, 2011, Systems biology of heart failure, challenges and hopes, Curr Opin Cardiol, 26, 314, 10.1097/HCO.0b013e328346597d Weinberg, 2002, Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction, Circulation, 106, 2961, 10.1161/01.CIR.0000038705.69871.D9 Azmi, 2010, Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations, Mol Cancer Ther, 9, 3137, 10.1158/1535-7163.MCT-10-0642 Roukos, 2010, Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care, Expert Rev Mol Diagn, 10, 33, 10.1586/erm.09.69 Prentice, 2004, Genomic and proteomic profiles of heart disease, Trends Cardiovasc Med, 14, 282, 10.1016/j.tcm.2004.08.001